Gilead reports positive HIV PrEP data for lenacapavir
Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...
The Pharma Letter1d
Lenacapavir efficacy shown in diverse range of patients
Gilead Sciences has announced new data from its pivotal Phase III PURPOSE 2 trial providing further details on the efficacy, ...
Gilead initiated with a Buy at Citi
Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...
Gilead reports results from pivotal Phase 3 PURPOSE 2 trial
Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...
MedPage Today1d
Novel Weekly Oral HIV Drug Safe in Early Trial of Healthy Volunteers
And then at the end of the talk, the presenter actually disclosed that this long-acting integrase inhibitor is being ...
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...
Daily Maverick6d
How South Africa can help secure immediate, global access to HIV prevention drug lenacapavir
We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.
FiercePharma6d
Gilead's CAR-T sales stagnate as Trodelvy takes another impairment hit
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...
The Lancet6d
New HIV drugs: access debates
Revolutionary new HIV drugs are being made available in 120 low-income countries, but many important populations are being left out. Sophie Cousins reports.
Gilead Sciences, Inc. (GILD) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Conference Call November 6, 2024 4:30 PM ETCompany ParticipantsDaniel O'Day - Chairman, Chief ...
Business Wire25d
Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral ...
Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...